EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study

Arvid Engström iD, Henrik Svanström, Anders Hviid, Björn Eliasson, Soffia Gudbjörnsdottir, Viktor Wintzell, Kristian Hveem, Christian Jonasson, Mads Melbye, Peter Ueda iD, Björn Pasternak

Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 5767-5778

DOI: 10.1111/dom.70760 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 17.04.2026. Verfasst von Arvid Engström und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Epidemiology Division, Department of Medicine, Centre for Pharmacoepidemiology, Solna, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Parkinson Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Lundbeck Foundation, Region Stockholm.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To investigate the association between use of GLP‐1 receptor agonists and incident Parkinson's disease. Material and Methods Cohort study using data from nationwide registers in Denmark, Norway and Sweden and an active‐comparator, new‐user design. We included 158 961 new users of GLP ‐1 receptor agonists and 188 065 new users of sulfonylureas, aged 45 years or older. Liraglutide accounted for 72.9% of GLP ‐1 receptor agonist follow‐up time, followed by semaglutide (13.4%), exenatide (7.3%), dulaglutide (5.1%) and lixisenatide (1.3%). The primary outcome was incident Parkinson's disease, defined as a first‐ever diagnosis of Parkinson's disease ( ICD ‐10 G20 ) or Parkinson's disease dementia ( ICD ‐10 F02 .3) in national patient registers. Cox regression with propensity score weighting was used to estimate hazard ratios ( HRs ) and control for confounding.

Results

Mean age was 65 years and 43% were female. Incidence rates for Parkinson's disease were 5.2 and 8.0 per 10 000 person‐years among GLP‐1 receptor agonist and sulfonylurea users, respectively (adjusted HR 0.81 [95% CI 0.68–0.96]). Results were consistent in a 2‐year lag‐time analysis (HR 0.84 [95% CI 0.70–1.02]) after excluding or censoring users of DPP‐4 inhibitors at cohort entry or during follow‐up (HR 0.74 [95% CI 0.60–0.93]) and in subgroup analyses by sex and age.

Conclusion

In this large observational cohort study, use of GLP‐1 receptor agonists compared with sulfonylureas was associated with a lower risk of incident Parkinson's disease. These findings support a potential neuroprotective role of GLP‐1 receptor agonists, though replication in additional studies is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsParkinson DiseaseAgedFemaleHumansMaleMiddle AgedCohort StudiesDenmarkExenatideGlucagon-Like PeptidesImmunoglobulin Fc FragmentsIncidenceInsulin SecretagoguesLiraglutideNorwayRecombinant Fusion ProteinsRegistriesSemaglutideSulfonylurea CompoundsSwedenGlucagon-Like Peptide 1

Stichwörter der Autor:innen

GLP‐1 analoguedisease preventionobservational studypharmaco‐epidemiology

Substanzen

dulaglutideExenatideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsInsulin SecretagoguesLiraglutidelixisenatideRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Clinical Epidemiology Division, Department of Medicine, Centre for Pharmacoepidemiology, Solna, Karolinska Institutet, Stockholm, Sweden.
  • Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
  • Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, Pharmacovigilance Research Center, University of Copenhagen, Copenhagen, Denmark.
  • Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • The Swedish National Diabetes Register, Vastra Gotalandsregionen, Gothenburg, Sweden.
  • Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.

ORCID-Profile: Arvid Engström, Peter Ueda

Förderung

  • Vetenskapsrådet
  • Lundbeck Foundation
  • Region Stockholm
  • Novo Nordisk Fonden
  • Dr. Margaretha Nilsson's Foundation for Medical Research
  • Karolinska Institutet
  • Strategic Research Area Epidemiology programme
  • Independent Research Foundation Denmark

Zitieren

APA

Engström, A., Svanström, H., Hviid, A., Eliasson, B., Gudbjörnsdottir, S., Wintzell, V., Hveem, K., Jonasson, C., Melbye, M., Ueda, P., & Pasternak, B. (2026). Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study. Diabetes, Obesity and Metabolism, 28(7), 5767-5778. https://doi.org/10.1111/dom.70760

Vancouver

Engström A, Svanström H, Hviid A, Eliasson B, Gudbjörnsdottir S, Wintzell V, et al. Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study. Diabetes, Obesity and Metabolism. 2026;28(7):5767-5778. doi:10.1111/dom.70760

BibTeX
@article{Engstrm2026,
  author = {Engström, Arvid and Svanström, Henrik and Hviid, Anders and Eliasson, Björn and Gudbjörnsdottir, Soffia and Wintzell, Viktor and Hveem, Kristian and Jonasson, Christian and Melbye, Mads and Ueda, Peter and Pasternak, Björn},
  title = {Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {7},
  pages = {5767--5778},
  doi = {10.1111/dom.70760}
}
Kostenlos starten →